Orasis Pharmaceuticals
Corrective Eye Drops for Presbyopia
Company Overview
Snapshot
Founded in September 2015, Orasis Pharmaceuticals operates with 51–200 employees. The company has raised a total of $121M across 5 funding rounds from 12 investors. In October 2024, Orasis Pharmaceuticals completed a $78M financing round led by.
Business overview
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on developing treatments for presbyopia, the age-related loss of near vision. Its core product, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, is an FDA-approved prescription eye drop designed as an alternative to reading glasses. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and medical biotechnology markets with its drug discovery and development efforts.
Strategic signal
In October 2024, Orasis Pharmaceuticals secured a $78 million financing round, led by. This significant capital infusion signals strong investor confidence in the company's market readiness and the commercial potential of its novel eye drop, positioning Orasis for a major entry into the ophthalmic market.
Log in to access full profile ›Company Intelligence Q&A
- What is Orasis Pharmaceuticals' primary product?
- Orasis Pharmaceuticals' primary product is QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, an FDA-approved prescription eye drop for the treatment of presbyopia, offering an alternative to reading glasses.
- When did Orasis Pharmaceuticals receive FDA approval for QLOSI™?
- Orasis Pharmaceuticals announced FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in October 2023.
- What was the purpose of the October 2024 financing round?
- In October 2024, Orasis Pharmaceuticals completed a $78 million financing round, led by.
- Has Orasis Pharmaceuticals expanded its commercial reach internationally?
- Yes, in October 2024, Orasis Pharmaceuticals announced a licensing agreement with Optus Pharmaceuticals for the commercialization of QLOSI™ eye drops in Korea.
- When did Orasis Pharmaceuticals submit its New Drug Application for CSF-1?
- Orasis Pharmaceuticals submitted a New Drug Application for its investigational novel eye drop candidate, CSF-1, for the treatment of presbyopia in January 2023.